87 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
to develop, manufacture and commercialize DACs directed to an initial undisclosed oncology target. Merck is responsible for all development, regulatory … in Greater China. Betta Pharma is responsible for all development, regulatory approval, manufacturing and commercialization costs in Greater China except
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
4 Mar 24
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
7:05am
, Darmstadt, Germany, will be responsible for clinical development and commercialization for drug candidates coming out of these programs.
About C4
8-K
CCCC
C4 Therapeutics Inc
4 Mar 24
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
7:05am
is responsible for all development, regulatory approval, manufacturing and commercialization costs. Under the terms of the License Agreement, MKDG has agreed
8-K
ve2 ohdyuab08pyha
12 Dec 23
Entry into a Material Definitive Agreement
7:15am
8-K
EX-99.1
20nvcvh yfl
12 Dec 23
Entry into a Material Definitive Agreement
7:15am
8-K
EX-99.1
vsv04i3wxvfy i9hhskw
20 Jun 23
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
7:11am
8-K
EX-10.1
td3 cc6jwg
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
5dmy5xz79jvx61wh8pf
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.2
hu1l76g
30 May 23
Entry into a Material Definitive Agreement
7:30am